A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

May 11, 2026 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

198

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Anhui
      • Bengbu, Anhui, China, 233000
        • The First Affillated Hospital of Bengbu Medical Universit
        • Contact:
      • Bozhou, Anhui, China, 236805
        • Bozhou People's Hospital
        • Contact:
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100020
        • Beijing Chao-Yang Hospital, Capital Medical University
        • Contact:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400038
        • Southwest Hospital, Third Military Medical University (Army Medical University)
        • Contact:
    • Gansu
      • Lanzhou, Gansu, China, 730000
        • Gansu Provincial People's Hospital
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Contact:
      • Guangzhou, Guangdong, China, 510000
        • The Third Affiliated Hospital of Sun Yat-Sen University
        • Contact:
      • Jiangmen, Guangdong, China, 529000
        • Jiangmen Central Hospital
        • Contact:
          • Chujun Ouyang, Bachelor
          • Phone Number: 13630480333
          • Email: chelly@126.com
      • Shenzhen, Guangdong, China, 518035
        • Shenzhen Second People's Hospital
        • Contact:
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • The First Affiliated Hospital of Guangxi Medical University
      • Nanning, Guangxi, China, 530007
        • The Second Affiliated Hospital of Guangxi Medical University
        • Contact:
    • Guizhou
      • Zunyi, Guizhou, China, 563000
        • The Affiliated Hospital of Zunyi Medical University
        • Contact:
    • Heilongjiang
      • Daqing, Heilongjiang, China, 163001
        • Daqing Oilfield General Hospital
    • Henan
      • Puyang, Henan, China, 457001
        • Puyang Oilfield General Hospital
        • Contact:
      • Xuchang, Henan, China, 461000
        • Xuchang Central Hospital
        • Contact:
      • Zhengzhou, Henan, China, 450003
        • The First Affiliated Hospital of Henan University of CM
        • Contact:
    • Hubei
      • Jingzhou, Hubei, China, 434020
        • Jingzhou Central Hospital
        • Contact:
      • Wuhan, Hubei, China, 430030
        • Tongji Hospital Tongji Medical College Of Hust
        • Contact:
      • Yichang, Hubei, China, 443100
        • Yichang Central People's Hospital
        • Contact:
          • Xiaoqiang Hou, Master
          • Phone Number: 13487237625
          • Email: hxqhjz@163.com
    • Hunan
      • Changsha, Hunan, China, 418000
        • Hunan University of Medicine General Hospital
        • Contact:
      • Zhuzhou, Hunan, China, 412007
        • ZhuZhou Central Hospital
        • Contact:
    • Jiangsu
      • Nanjing, Jiangsu, China, 210001
        • Jiansu PeopinceHospital
        • Contact:
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • The First Affiliated Hospital of Nanchang University
        • Contact:
    • Jilin
      • Changchun, Jilin, China, 130021
        • The First Hospital of Jilin University
        • Contact:
      • Changchun, Jilin, China, 130000
        • DAQING OILFIELD GENERAL HOSPITAL DAQING Jilin Provincial People's Hospital
        • Contact:
    • Shaanxi
      • Xi'an, Shaanxi, China, 710000
        • The First Affiliated Hospital of Air Force Medical University
        • Contact:
      • Xi'an, Shaanxi, China, 710000
        • The Second Affiliated Hospital of Air Force Medical University
        • Contact:
    • Shandong
      • Weifang, Shandong, China, 261000
        • Weifang People's Hospital
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200001
        • Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
        • Contact:
    • Shanxi
      • Linfen, Shanxi, China, 041000
        • Linfen Central Hospital
        • Contact:
    • Sichuan
      • Yibin, Sichuan, China, 644000
        • The first People's Hospital of Yibin
        • Contact:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300052
        • Tianjin Medical University General Hospital
        • Contact:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310009
        • the Second Affiliated Hospital Zhejiang University School of Medicine
        • Contact:
      • Taizhou, Zhejiang, China, 318000
        • Taizhou Central Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sign a written informed consent form, which must meet the following requirements:

    • Willingness to participate in the study and ability to sign an informed consent form.
    • Willingness and ability to complete all research-related procedures and site visits.

  • Characteristics of participants in the Systemic Lupus Erythematosus (SLE) trial:

    • Screen for patients with a confirmed diagnosis of SLE dating back to at least 24 weeks prior to the visit.
    • Diagnosed with systemic lupus erythematosus according to the 2019 classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
    • Meet one of the following criteria: elevated levels of antinuclear antibodies (ANA) ≥ 1:80, positive results for anti-double-stranded DNA (anti-dsDNA) (positive results include indeterminate results), or positive results for anti-Smith (anti-Sm) antibodies.
    • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) score ≥ 8 and clinical SLEDAI-2K score ≥ 4, with involvement of joints and/or skin vasculitis and/or rash manifestations (Note: Clinical SLEDAI-2K manifestations do not include complement deficiency and positivity for anti-ds-DNA antibodies).
  • Age between 18 and 75 years old (based on the date of signing the informed consent form).

  • Medications for SLE treatment:

    • Prior to the screening visit, there must be a period of background therapy of at least 12 weeks. The therapy must have been administered at a stable dose for at least 4 weeks prior to the screening visit and remain stable until randomization and throughout the duration of the study participation. If antimalarial or immunosuppressive therapy is discontinued prior to the screening visit, the last dose must have been administered at least 4 weeks prior. Detailed information on specific medications is as follows:

      1. Immunosuppressants (can be used only one type; combination use is not permitted): Antimalarial drugs: Hydroxychloroquine (allowed for monotherapy; allowed in combination with one type of immunosuppressant) (maximum 400 mg/day).
      2. Duration of clearance when using other immunomodulatory drugs or biologics.
    • Corticosteroids (CS) (prednisone or equivalent medication) is permitted but not required as background therapy. For trial participants using CS, the dose must be stable for at least 2 weeks prior to the screening visit, not exceed 40 mg/day during screening, and remain stable prior to randomization. Monotherapy with CS is not permitted.

    • The requirements for trial participants currently receiving long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are as follows:

      1. The dosage must remain stable for a period of 14 days prior to the screening visit and must remain stable until randomization and throughout the study period. The use of NSAIDs alone is not permitted.
      2. A maximum of one oral NSAID (at a stable dosage) may be used during the study period.
      3. The concurrent use of aspirin as a cardiovascular protective agent/to prevent thrombosis (in addition to other NSAIDs) is permitted throughout the study period, provided that the dosage remains stable.
  • Women of childbearing age must agree to use effective contraceptive measures during the study period and for 6 months thereafter, and undergo a blood pregnancy test that is negative within 7 days prior to enrollment in the study. Men must agree to use effective contraceptives during the study period and for the subsequent 6 months.

Exclusion Criteria:

  • Conditions other than SLE:

    • drug-induced SLE;
    • Trial participants with other autoimmune diseases (e.g. multiple sclerosis, psoriasis, inflammatory bowel disease, etc.) were excluded. Test participants with secondary dry syndrome could not be excluded;
    • Excluded trial participants with overlapping syndromes of SLE, such as systemic sclerosis and mixed associative weaving disease;
    • In the case of a combination of antiphospholipid syndrome secondary to systemic lupus erythematosus, prior severe blood clots / obstetric complications need to be ruled out; Prophylaxis with low-dose aspirin (50-100 mg / d) in the absence of thrombotic events or obstetric comorbidities and with high-risk antiphospholipid antibody (aPL) characteristics may be included;
    • Trial participants who had had lupus encephalopathy before screening were excluded;
    • Excluding active, severe lupus nephritis requiring cytotoxic drugs (CTX) or high-dose CS treatment, excluding lupus pinocytosis, thrombotic microangiopathy; Trial participants with lupus nephritis, but who are currently controlled, may be included;

  • Other medical conditions and medical history;

    • Study participants who are pregnant or breastfeeding;
    • Evidence of a significant disease / condition or unstable clinical condition (e.g. kidney, Liver, blood, gastrointestinal, endocrine, lung, immune, psychiatric) or locally active infection / infectious disease which, according to medical judgement, will significantly increase the risk of the trial participants if they participate in the study;
    • Have had any major surgery within 30 days prior to the first dose of the study treatment, or planned to have any surgery during the course of the study;
    • Cancer or a history of cancer or lymphotrophic disease within the past 5 years (except adequately treated basal cell carcinoma or squamous cell carcinoma with no evidence of recurrence);
    • Class III or IV congestive heart failure as defined by the New York Heart Association (NYHA) or any recent episode of heart failure resulting in symptoms of NYHA Class III / IV; Or a history of clinically significant ventricular arrhythmia (e.g. persistent ventricular arrythmia , ventricular tremor, sharp twisted ventricular articular arrhythmia) or an arrhythmia that requires continuous anti-arrhythmic medication;
    • A history of acute coronary syndrome (e.g. myocardial infarction, unstable angina) and / or any major cerebrovascular disease within 24 weeks prior to screening;
    • Currently or recently (within 3 months prior to randomization) had a gastrointestinal disease, including gastrointestinal surgery, that was likely to affect treatment absorption in the study;
    • In medical judgment, the trial participants had non-SLE concomitant conditions that may require additional systemic corticosteroid therapy during the study (e.g., asthma);
    • Severe blood loss (> 500 mL) or transfusion within 4 weeks prior to randomization;
    • It is not possible to take the drugs orally;
    • Unable to receive venous punctures and / or tolerate venous pathways;
    • Persons who have a history of substance abuse and cannot quit or who have psychiatric disorders;
    • Any other medical, spiritual and / or social reasons determined by medical judgement;

  • Previous and combined drug use:

    • Unable to adhere to restricted and prohibited treatments; Unable to comply with the discontinuation requirement;
    • Use more than one immunosuppressant;
    • Previous exposure to other TYK2 inhibitors;
    • Participants who were previously exposed to anti-interferon targeted drug trials such as Anilumab, Rontalizumab, nterferon Alpha Kinoid (INFaKinoid), etc.;
    • Other research drugs must be discontinued for at least 12 weeks or 5 half-lives (whichever is longer) before screening.

  • Infection Related:

    • Chest radiology within 6 months prior to screening showed the presence of active Tuberculosis (TB) in the trial participants. Test participants who were negative for chest radiology within 3 months prior to screening were eligible to participate in the study:
    • Hepatitis C, hepatitis B, or human immunodeficiency virus (HIV) infection, characterized by antibodies to hepatitis C (anti-HCV) and all HCV-RNA positive, surface antigens to hepatitis B (HBsAg) positive, core antibodies to the hepatitis A (HBcAb) and all HIV-DNA positive, or HIV antibody screening positive;
    • is currently receiving any treatment regarding chronic infections;
    • Persons in need of treatment for syphilis;
    • Have a congenital or acquired immunodeficiency disorder;
    • Have a history of repeated infections requiring hospitalization or treatment outside the bowel (muscle or intravenous) and receiving intravenous antibiotics; Or need to be hospitalized and / or given intravenous anti-infective treatment within 30 days of the random, or receive any infection requiring oral anti-infectious treatment within 14 weeks of the random;
    • Prior history of systemic shingles; Or have two or more recurrent shingles in two years; Or the shingles infection did not completely subside within 12 weeks prior to screening;
    • Vaccinated live within 90 days of randomization or inactivated within 30 days of randomisation;

  • Abnormalities in physical or laboratory tests:

    • Clinically significant chest X-ray or ECG abnormalities
    • A laboratory test of clinical significance is abnormal. A screening period laboratory test with abnormal results may be repeated once to confirm abnormal results. If the results are restored to programme acceptable during the screening period without intervention, trial participants may be admitted to the study;
    • Any other significant laboratory abnormalities that may, in medical judgement, pose an unacceptable risk to the trial participants during the study period;

  • Other exclusion criteria:

    • Have a history of any significant drug allergy (e.g. causing an allergic reaction or causing liver toxicity); He is known to be allergic to the ingredients of research drugs;
    • those who are unable to comply with the pilot programme;
    • Persons who are ready to undergo or have previously undergone a heterotopic bone marrow transplant or a solid organ transplant;
    • In the judgement of the investigator, there is a situation that seriously endangers the safety of the test participants or affects the completion of the study by the test participant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 16 mg TQH3906 capsule
16 mg TQH3906 capsule, oral administration, once daily, for a duration of 48 weeks.
Drug: TQH3906 capsule
The TQH3906 capsule is a Tyrosine Kinase 2 (TYK2) inhibitor.
Experimental: 24 mg TQH3906 capsules
24 mg TQH3906 capsule, oral administration, once daily, for a duration of 48 weeks.
Drug: TQH3906 capsule
The TQH3906 capsule is a Tyrosine Kinase 2 (TYK2) inhibitor.
Placebo Comparator: TQH3906 placebo
Placebo, oral administration, once daily, for a duration of 48 weeks.
Drug: TQH3906 placebo
Placebo without drug.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percentage of participants who achieved Systemic Lupus Erythematosus Responder Index 4 (SRI-4)
Time Frame: Baseline to week 32.
The percentage of trial participants who reached SRI-4 by week 32.
Baseline to week 32.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percentage of participants who achieved SRI-4
Time Frame: Baseline to week 24, baseline to week 48
The percentage of trial participants who reached SRI-4 by weeks 24 and 48
Baseline to week 24, baseline to week 48
Percentage of trial participants achieving composite lupus assessment (BICLA) remission based on the British Isles Lupus Assessment Group (BILAG) index
Time Frame: Baseline to week 24, baseline to week 32, baseline to week 48
Percentage of trial participants achieving composite lupus assessment according to the British Isles Lupus Assessment Group (BILAG) index by weeks 24, 32, and 48 (BICLA remission)
Baseline to week 24, baseline to week 32, baseline to week 48
The percentage of trial participants who achieved low disease activity status (LDA) for lupus
Time Frame: Baseline to week 24, baseline to week 32, baseline to week 48
The percentage of trial participants who achieved low disease activity status (LDA) for lupus by weeks 24, 32, and 48
Baseline to week 24, baseline to week 32, baseline to week 48
The proportion of trial participants with baseline Clinical Lupus Activity Index (CLASI) activity score ≥ 10 and achieving CLASI response (defined as a reduction in CLASI activity score of ≥ 50% from baseline at weeks 24, 32, and 48)
Time Frame: Baseline to week 24, baseline to week 32, baseline to week 48
The proportion of trial participants with baseline Clinical Lupus Activity Index (CLASI) activity score ≥ 10 and achieving CLASI response (defined as a reduction in CLASI activity score of ≥ 50% from baseline at weeks 24, 32, and 48)
Baseline to week 24, baseline to week 32, baseline to week 48
The percentage of trial participants who achieved a joint count of 50 (defined as having ≥ 6 joints affected at baseline and a reduction in joint involvement of ≥ 50% from baseline)
Time Frame: Baseline to week 24, baseline to week 32, baseline to week 48
Percentage of trial participants who achieved a joint count of 50 (defined as having ≥ 6 joints affected at baseline and a reduction in joint involvement of ≥ 50% from baseline) by weeks 24, 32, and 48
Baseline to week 24, baseline to week 32, baseline to week 48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

March 28, 2026

First Submitted That Met QC Criteria

March 28, 2026

First Posted (Actual)

April 3, 2026

Study Record Updates

Last Update Posted (Actual)

May 12, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TQH3906-II-03

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Systemic Lupus Erythematosus

Clinical Trials on TQH3906 capsule

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe